What Ultracef (Cefprozil) Treats: Main Uses and Benefits

The use of Ultracef is characterized by its various therapeutic indications for bacterial infections. This medication is commonly used across domains where additional symptomatic support is needed for acute bacterial infections.

Ultracef is primarily relevant in contexts involving heightened systemic burden, such as infections of the upper respiratory tract (pharyngitis, tonsillitis, acute sinusitis), the middle ear (acute otitis media), the lower airways (acute bacterial exacerbation of chronic bronchitis), and uncomplicated infections of the skin and urinary tract. It is applied when groups of symptoms, including severe sore throat, earache, fever, and localized pain, become more disruptive during flare-ups. The medication is considered relevant for easing symptoms associated with these acute, unstable patterns.

“Its application supports symptomatic relief during difficult episodes, assisting patients with coping and contributing to the overall symptom management.”

Quick Fact: Supporting Management of Localized Discomfort

Quick Fact: Supporting Management of Localized Discomfort

Ultracef is relevant for managing symptoms that interfere with daily comfort and may assist in supporting functional stability in conditions characterized by periods of heightened symptoms.

Regulatory References

1. NIH National Library of Medicine

Ultracef (Cefprozil) is a prescription cephalosporin antibiotic used to treat bacterial infections in various parts of the body, including the ears, sinuses, throat, tonsils, bronchi (bronchitis), and skin/soft tissue. It is not effective against viral infections like the common cold or flu, and its use is reserved for infections proven or strongly suspected to be caused by susceptible bacteria.

Who Can Use Cefprozil?

Cefprozil is typically prescribed for both adults and pediatric patients. Dosages are adjusted based on the specific infection and the patient's age and weight, especially in children. Safety and efficacy have been established in children as young as six months for certain indications, such as acute otitis media.

Who Cannot Use Cefprozil?

Cefprozil is contraindicated in patients with a known allergy or hypersensitivity to cefprozil itself, any component of the formulation, or other cephalosporin antibiotics.

Caution is advised and a physician must be informed if a patient has a history of:

• Allergy to penicillin antibiotics (due to the potential for cross-sensitivity).
• Gastrointestinal disease, particularly a history of colitis or severe diarrhea.
• Kidney impairment, as dosage adjustments may be necessary.

Safety data for use in newborns and infants younger than six months for many indications is limited, and use should be determined by a healthcare provider. Patients who are pregnant or breastfeeding should discuss the risks and benefits with their doctor.

Interactions with other medicines and products

Official regulatory information for Ultracef (Cefprozil) outlines specific patterns of interaction based on pharmacokinetic and pharmacodynamic effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance(s)	Official Outcome	Constraint
Renal Clearance	Probenecid	Doubles the Area Under the Curve (AUC) of Cefprozil due to reduced renal excretion.	Clinically significant exposure increase.
Nephrotoxicity Risk	Aminoglycosides	Nephrotoxicity has been reported when combined with cephalosporins.	Use with caution, especially with compromised renal function.
Nephrotoxicity Risk	Potent Diuretics	Advised caution due to potential adverse effects on renal function.	Increased risk of adverse renal effects.

Administration and Test Interference

Co-administration of Cefprozil with antacids has been officially documented as not affecting the medicine's bioavailability, negating the requirement for a mandatory time separation. The oral suspension formulation contains phenylalanine (28 mg per 5 mL), which is a mandatory regulatory note for patients with Phenylketonuria (PKU).

Cefprozil can cause interference with certain diagnostic procedures. It may produce a false-positive result for glucose in urine tests using non-enzymatic methods (e.g., Clinitest). Additionally, a positive direct Coombs' test has been reported during treatment with cephalosporins.

How Ultracef (Cefprozil) Works

Cefprozil is a bactericidal antibiotic that operates by critically disrupting the structural integrity of susceptible bacteria, resulting in the death of susceptible bacteria. This action is accomplished via two principal mechanistic domains that form a lethal cascade.

Molecular Inactivation of Bacterial Enzymes

The drug initiates its action by targeting essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which function as D,D-transpeptidases. Cefprozil's core structure forms a stable, covalent bond with the active site of these PBPs, causing their irreversible inactivation. This mechanism directly arrests the enzyme-driven process of building the bacterial cell's protective outer wall.

Lysis through Arrest of Cell Wall Synthesis

The inhibition of PBP function halts the peptidoglycan cross-linking pathway, preventing the formation of a rigid cell wall. Without this structural support, the bacterial cell cannot withstand its own high internal osmotic pressure, leading to Cell Lysis. This physiological consequence—the immediate physical destruction of the bacteria—is the basis of Cefprozil's bactericidal effect.

How to Use Ultracef (Cefprozil)

Ultracef (Cefprozil) is an oral medication administered according to specific regimens. The drug is exclusively formulated for oral use, available as a tablet (250 mg and 500 mg) or as a powder for oral suspension (125 mg/5 mL and 250 mg/5 mL).

Standard Administration Principles

Dosing Frequency: Cefprozil is prescribed to be taken at fixed intervals, either once daily (q24h) or twice daily (q12h), depending on the specific regimen. The medication may be taken without regard to meals; the time of intake relative to food does not alter the extent of the drug's absorption.

Dosing Regimens:

Patient Group	Frequency Pattern	Standard Dosing Range
Adults (ge 13 years)	Once or twice daily	250 mg to 500 mg per dose
Pediatric (6 months to 12 years)	Once or twice daily	7.5 mg/kg to 20 mg/kg per dose

Course Duration and Procedural Requirements

Duration of Therapy: The standard treatment course is typically 10 days. For infections caused by Streptococcus pyogenes, a minimum course of 10 days is required to complete the full treatment protocol.

Handling: The oral suspension requires that the liquid be shaken well immediately prior to each dose to ensure uniform dispersion. If a scheduled dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next dose, in which case the missed dose is skipped; doses must not be doubled.

Special Population Adjustment: A dosage reduction of 50% is required for patients with significantly impaired renal function (Creatinine Clearance < 30 mL/min), while the dosing interval is maintained. No dose adjustment is recommended for older adults or patients with hepatic impairment based on age or liver function alone.

Research evidence / Overview of Studies for Ultracef (Cefprozil)

This section outlines the types of official clinical research that have been conducted on Cefprozil, the measures the studies tracked, and the areas where the research remains limited. It is a descriptive summary of the evidence landscape and does not offer clinical advice or interpret individual outcomes.

---

Evidence for Use in Respiratory Tract Infections (Upper and Lower)

Research has explored the use of Cefprozil for various respiratory conditions; studies were also evaluated for lower respiratory conditions like acute bacterial exacerbations of chronic bronchitis (AECB). Studies were typically Randomized Controlled Trials (RCTs) and multicenter comparative trials, including both adult patients and children over the age of two.

The research examined outcomes related to physical discomfort and systemic imbalance. For instance, trials monitored changes in key respiratory symptoms and assessed the rate of microbiological assessment (monitoring if targeted bacteria were still detectable). Findings observed in these short-term studies contributed to the broader evidence landscape.

Evidence for Use in Middle Ear Infections (Acute Otitis Media)

The evidence for use in acute otitis media (AOM), a condition characterized by episodic manifestations, primarily comes from controlled clinical trials and meta-analyses. These studies focused specifically on pediatric patients starting from six months of age. The trials monitored outcomes by tracking rates of clinical response and microbiological assessment at defined follow-up visits.

---

Long-Term Studies and Durability of Response

The majority of clinical trials for Cefprozil were conducted during periods of increased symptom activity and were designed to assess immediate or short-term symptom changes. While some studies, particularly for uncomplicated UTIs, extended their monitoring period up to 4–6 weeks, durability of outcome is not fully established across all indications. The research provides insight into short-term changes but evidence is limited regarding the durability of the observed response over extended time intervals.

What is Still Uncertain About Ultracef (Cefprozil) in Research

Research highlights what is known—and what is still uncertain—about Cefprozil. One formally acknowledged research limitation is the evidence base for pharyngitis: Substantial data on subsequent rheumatic fever prevention following a strep throat infection are not fully established. Furthermore, much of the evidence is derived from settings with varying symptom burdens where the drug was assessed against an active comparator, meaning the findings describe group patterns related to comparative equivalence rather than the agent's absolute effect size. The results apply only to the populations studied, and there is limited information for more complex or resistant infection types.

Key Studies & References Cefprozil Tablet - DailyMed (Official Labeling and Indication Data)

Common questions about Ultracef (Cefprozil) (FAQ)

Q: What should I do if I miss a dose of Ultracef?

If a dose is forgotten, it is typically taken as soon as it is remembered. However, if the time is almost right for the next scheduled dose, the missed dose is generally skipped. Official administration guidelines indicate that doses should not be doubled to compensate for a missed dose.

---

Q: Does Ultracef (Cefprozil) cause drowsiness or affect my ability to drive?

Official product information for Cefprozil reports that dizziness is a possible side effect. While the specific impact of dizziness or other central nervous system effects on an individual's ability to drive is not fully detailed, awareness of this potential side effect may be necessary when performing tasks that require concentration.

---

Q: Can Ultracef treat the flu or common cold?

No, Cefprozil is an antibiotic, and official labeling states it is not effective against viral infections, which include the common cold or the flu. Its use is specifically reserved for treating infections that are proven or strongly suspected to be caused by susceptible bacteria.

---

Q: Is Ultracef safe to take during pregnancy?

Cefprozil is classified as Pregnancy Category B, according to regulatory documents. This classification means that animal reproduction studies have not shown a risk to the fetus. However, regulatory sources note that there are no adequate and well-controlled studies conducted specifically in pregnant women.

---

Q: Is there a maximum daily dosage for Cefprozil?

Official labeling establishes a maximum dose for Cefprozil, particularly for certain pediatric groups (children 6 months to 12 years of age). For certain infections, the maximum recommended daily dose for this age group is 1 gram per day (1000 mg/day). Dosage information is determined by a healthcare provider and should be strictly adhered to.

---

Q: Does Ultracef interact with alcohol?

Regulatory documents do not list a specific formal drug interaction or contraindication with ethyl alcohol in the core product labeling. Patients are generally advised to discuss alcohol consumption with a healthcare professional while taking any medication, particularly antibiotics.

---

Q: What is the age limit for using Ultracef?

Official information indicates that safety and efficacy have been established for use in pediatric patients as young as six months for certain infections. The label also addresses use in older adults (ge 65 years old), noting that typically no dosage adjustment is required based on age alone.

---

Q: What are the symptoms of an allergic reaction to Cefprozil?

Symptoms of a potential allergic reaction reported in official safety information may include hives, rash, difficulty breathing, or swelling of the face, lips, tongue, or throat. The regulatory profile also notes the potential for more severe, though rare, reactions such as anaphylaxis and serum sickness-like reactions.

Official Storage and Disposal Requirements

Official regulatory information specifies distinct storage conditions for Cefprozil's two forms to ensure the stability of this antibacterial agent.

Form	Storage Environment	Stability/Prohibited Conditions
Oral Tablets	Controlled Room Temperature (20 C to 25 C).	Protect from excess heat, moisture, and direct light.
Oral Suspension (Constituted)	Refrigerator (2 C to 8 C).	Must be discarded after 14 days; do not freeze.

All forms must be kept in the tightly closed, original container and secured out of the sight and reach of children.

For disposal, unused or expired medication should be taken to a drug take-back program. As an alternative, and since Cefprozil is not on the FDA's flush list, it may be mixed with an undesirable substance, sealed in a bag, and placed in the household trash.